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ABSTRACT
Detection of circulating tumor cells remains a significant challenge due to their 
vast physical and biological heterogeneity. We developed a cell-surface-marker-
independent technology based on telomerase-specific, replication-selective oncolytic 
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herpes-simplex-virus-1 that targets telomerase-reverse-transcriptase-positive cancer 
cells and expresses green-fluorescent-protein that identifies viable CTCs from a broad 
spectrum of malignancies. Our method recovered 75.5–87.2% of tumor cells spiked 
into healthy donor blood, as validated by different methods, including single cell 
sequencing. CTCs were detected in 59–100% of 326 blood samples from patients 
with 6 different solid organ carcinomas and lymphomas. Significantly, CTC-positive 
rates increased remarkably with tumor progression from N0M0, N+M0 to M1 in each 
of 5 tested cancers (lung, colon, liver, gastric and pancreatic cancer, and glioma). 
Among 21 non-small cell lung cancer cases in which CTC values were consecutively 
monitored, 81% showed treatment-related decreases, which was also found after 
treatments in the other solid tumors. Moreover, monitoring CTC values provided an 
efficient treatment response indicator in hematological malignancies. Compared to 
CellSearch, our method detected significantly higher positive rates in 40 NSCLC in all 
stages, including N0M0, N+M0 and M1, and was less affected by chemotherapy. This 
simple, robust and clinically-applicable technology detects viable CTCs from solid and 
hematopoietic malignancies in early to late stages, and significantly improves clinical 
detection and treatment prognostication.
INTRODUCTION
Circulating tumor cells (CTCs) shed from the 
primary tumor site enter the circulation and may spread 
to other locations and initiate regional nodal or distant 
metastases [1, 2, 3, 4]. CTCs comprise a low percentage 
of circulating cells commonly present in cancer patients. 
With numbers as low as one CTC per 106–107 peripheral 
blood leukocytes, enrichment, investigation, and 
quantification of CTCs has proven extremely difficult 
[5], but the effort has been validated by current studies 
showing that the presence of CTCs in peripheral blood is 
a valuable prognostic marker in cancer patients [6, 7, 8, 9, 
10, 11, 12], and an useful predictor of progression-free and 
overall survival. Results from clinical studies have shown 
breast, prostate and colorectal cancer patients with fewer 
CTCs in their peripheral blood survived longer than those 
with more CTCs [7, 8, 13]. Characterizing CTCs during 
drug treatment could also predict patient responses to 
specific anticancer drugs [14, 15, 16, 17], and some studies 
suggest that further investigation of CTCs could provide 
a clinically-relevant strategy to accurately determine 
cancer stage and/or treatment efficacy [18, 19]. There are 
currently a variety of methods to detect and quantify CTCs 
in peripheral blood [20, 21, 22], the majority of which are 
designed to identify the size of CTCs, antibodies against 
cell-surface molecules, or biological characteristics of 
cancer cells. Although these methods show some promise 
in detecting CTCs, they have limitations or are impractical 
for clinical use. 
The most common current CTC identification 
techniques rely on antibodies against cell-surface 
molecules [20] using various antigens, such as EpCAM 
and cytokeratins (CKs), as markers for CTC detection 
or isolation. However, many studies have clearly shown 
that cell surface markers are different in different tumor 
cells [23, 24, 25], resulting in detection of only a subset of 
CTCs and subsequent underestimation of CTC numbers 
due to cell surface marker-negative CTC subsets [6, 26]. 
In addition, cell-surface marker-dependent approaches 
do not distinguish between viable or dead cells [27, 28]. 
Clearly, more sensitive, specific and reliable methods are 
needed for clinically meaningful application.
Measurement of CTC number during drug treatment 
could also predict the response to specific anticancer 
drugs [14, 15, 16, 17], and some studies suggest that 
CTC counts could be a clinically-relevant strategy to 
accurately determine cancer stage and/or treatment 
efficacy [18, 19]. Development of such methods will 
require further investigation into the source, biology and 
ultimate function of CTCs since their prognostic value has 
been verified only in a limited number of cancer types, e.g. 
breast, prostate and colorectal cancers.
An adenovirus system (OBP-401) for CTC 
detection based on biological characteristics of cancer 
cells has been reported [29], but while this system 
identified and enumerated viable CTCs, it had significant 
detection limitations. This system used a size threshold 
to define GFP-positive CTCs, but because tumor cells 
are heterogeneous in size [20, 30], OPB-401 may detect 
only a subset of larger CTCs. Moreover, OBP-401 failed 
to isolate CTCs by flow cytometry for subsequent single 
CTC analysis related to biologically-relevant mutations, 
new drug-resistance genes, new tumor markers, etc. 
Furthermore, the Ad-system cannot identify CTCs in 
patients with hematological malignancies. Adusumilli 
et al. [31] also reported the use of tumor-selective HSV 
expressing GFP to detect cancer cells in body fluids.
We previously reported the construction of an 
hTERT promoter-regulated oncolytic Herpes Simplex 
virus-1 (oHSV1-hTERT-GFP) in which the key 
transcriptional regulatory protein of HSV-1 was controlled 
by the hTERT promoter core sequence [32]. Here, we 
show that oHSV1-hTERT-GFP was strictly replicated in 
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malignant tumor cells with detectable telomerase activity 
in vivo and in vitro, and this restricted replication did 
not cause lysis of the tumor cells within 48 hours post 
virus transduction. We further established a novel and 
highly applicable oHSV1-hTERT-GFP-based method to 
selectively label rare human CTCs in peripheral blood 
using GFP expression, which can be monitored by flow 
cytometry or fluorescence microscopy. This method not 
only allows specific detection and enumeration of viable 
CTCs independent of epithelial marker status, but may 
also permit molecular and genetic profiling of CTCs.
RESULTS
Labeling human cancer cells with oHSV1-
hTERT-GFP
To determine the correlation between hTERT 
and GFP expression in various human cancer cell lines 
following oHSV1-hTERT-GFP transfection, quantitative 
real-time polymerase chain reaction (qRT-PCR) for 
hTERT, and flow cytometry for GFP were performed in 
parallel. These data showed that the fluorescence intensity 
of GFP directly correlated with hTERT expressed in the 
various cancer cell lines (Figure 1A). GFP expression 
in EpCAM-positive or -negative cancer cell lines 
was evaluated, and both the EpCAM-positive human 
hepatocellular carcinoma cancer cell line, Huh7, and the 
EpCAM-negative hepatocellular carcinoma cancer cell 
line, SMMC-7721, exhibited GFP expression as early 
as 12 hours after oHSV1-hTERT-GFP transduction at 
Multiplicity of infection (MOI) = 1 (Figure 1B and 1C). 
Moreover, GFP fluorescence intensity increased over 
time, resulting in a strong GFP signal in nearly all cells 
24 hours after transduction. In parallel experiments, 
oHSV1-hTERT-GFP also induced GFP expression in 7 
other hTERT-positive cancer cell lines, including human 
gastric cancer cell BGC823, human lung cancer cell A549, 
human prostate cancer cell PC3, human osteosarcoma cell 
Hos, human glioma cell U251, human hepatocarcinoma 
cell BEL-7402, and HepG2, within 24 hours after 
transduction (Supplementary Figure 1).
Elimination of oHSV1-hTERT-GFP-transduced 
white blood cells using fluorescent anti-CD45 
antibody and FACS
We noted in our preliminary investigation that 
a few white blood cells (WBCs) were transduced by 
oHSV1-hTERT-GFP, leading to the transient expression 
of GFP driven by the CMV promoter, which raised the 
concern that these GFP-positive (GFP+) WBCs might 
interfere with detection of tumor cells in the blood. Since 
all WBCs contain the CD45 cell surface marker, an anti-
CD45 antibody was used in FACS analysis to remove 
all CD45-positive cells, including the virus-transduced 
GFP+ WBCs. Ten WBC samples from healthy donors 
were incubated with the virus at MOI = 1 for 24 hours 
followed by staining with a PE/Cy5-labeled CD45 
antibody. FACS analysis revealed that the GFP+ cell 
numbers (including CD45+) were between 4–15 cells 
per 105 WBCs and 47– 133 cells per 106 WBCs (n = 10), 
whereas the average CD45–/GFP+ cells were both 0.0 
per 105 WBCs and per 106 WBCs (Figure 2). Therefore, 
the CD45–/GFP+ cells were used to represent CTCs 
throughout our investigation. 
Accuracy of the oHSV1-hTERT-GFP approach 
in various mimic CTC models
To test the efficacy and accuracy of the oHSV1-
hTERT-GFP detection method, variable numbers of 
human cancer cell lines, including BGC823, Huh7 and 
SMMC- 7721, were spiked into whole blood samples 
from healthy donors and analyzed using the oHSV1-
hTERT-GFP replication methods. As shown in Figure 3A, 
the recovery rate of BGC823 cells was 75.5–87.2% over 
the frequency range of cancer cell numbers indicated 
(Supplementary Table 1). Regression analysis of the 
number of CD45−/GFP+ cells versus the number of spiked 
tumor cells showed a strong correlation (r2 = 0.9909). 
The HuH7 and SMMC-7721 cell tests also exhibited 
correlation efficiencies of r2 = 0.9876 and 0.9897, 
respectively (Figure 3B and 3C, Supplementary Tables 2 
and 3). The GFP+ cells representing the spiked tumor 
cells were also visualized by fluorescence microscopy 
(Figure 3D), and the results suggest that the number of 
CD45–/GFP+ cells detected by our method was clinically 
relevant and reflected numbers of CTCs expected in 
peripheral blood. 
Validation of the origin of the CD45–/GFP+ cells 
by single-cell sequencing
To confirm that oHSV1-hTERT-GFP-labeled cells 
were cancer cells and not normal cells, SMMC- 7721 
cancer cells were spiked into a peripheral blood sample 
from a healthy donor, exposed to oHSV1-hTERT-GFP, 
and CD45–/GFP+ and CD45+/GFP– cells isolated 
(Figure 4A). Six single cells from the CD45–/GFP+ 
population, three single cells and one pooled cell from 
the CD45+/GFP– population, were whole-genome 
amplified and the product examined. The results showed 
that a single band was obtained only from PCR products 
containing sufficient amounts of oHSV1-hTERT-GFP 
DNA. Furthermore, Sanger sequencing showed that the 
PCR-positive products matched the DNA sequence of 
oHSV1-hTERT-GFP, which implies that all 6 CD45–/
GFP+ single cells efficiently replicated oHSV1-hTERT-
GFP, while none of the 3 CD45+/GFP– single cells or the 
CD45+/GFP– cell pool were capable of replicating the 
intracellular virus (Figure 4B).
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Next, we sequenced the amplification products of the 
9 single cells at a depth of ~5× as well as the unamplified 
bulk DNA of the SMMC-7721 cell line and the peripheral 
blood of the healthy donor at ~50× depth and pooled cells 
at ~20× depth, and evaluated the whole exome recovery 
and amplification uniformity of single-cell sequencing 
using a Circosmap [33]. The mean coverage rate (≥ 1×) of 
single-cell sequencing in the exome regions was 70.62% 
(range 52.50–87.03%) at a 6.6× mean sequencing depth 
(Supplementary Table 4). According to the sequence 
recovery and distribution uniformity of the whole exome, 
the single-cell sequencing data showed uniform whole-
exome coverage, highly similar to that of the unamplified 
bulk (Figure 4C).
After single nucleotide polymorphisms (SNPs) 
calling, the SNPs of each sample were separated into 
4 subsets (S1–4) that clearly distinguished the source of the 
single cells (Figure 4D). Single-nucleotide substitutions of 
Figure 1: oHSV1-hTERTp-GFP selective replication in human cancer cells. (A) The relative hTERT expression level and GFP 
fluorescence intensity in human tumor cell lines as determined by real-time RT-PCR analysis and flow cytometry, respectively. Relative 
hTERT mRNA expression ratios were normalized to the BGC823 cell line. Relative GFP fluorescence intensity was measured 48 hours after 
oHSV1-hTERTp-GFP transduction at an MOI of 0.1 and normalized to the BGC823 cell line. (B) Fluorescence micrographs showing GFP 
expression (bottom panels) of EpCAM+ HuH7 cells 48 hours after oHSV1-hTERTp-GFP transduction at an MOI of 1, and corresponding 
phase-contrast microscopy images of cell morphology (top panels). Original magnification, ×100. (C) Fluorescence micrographs showing 
GFP expression (bottom panels) of EpCAM- SMMC-7721 cells 48 hours after oHSV1-hTERTp-GFP transduction at an MOI of 1, and 
corresponding phase-contrast microscopy images of cell morphology (top panels). Original magnification, ×100.
Figure 2: The number of GFP-positive cells per 106 white blood cells after oHSV1-hTERT-GFP infection. The columns 
marked GFP+ represent the total GFP+ cells investigated by our approach, and GFP+ cells include CD45+ and CD45−. Each value 
represents the mean ± SED of ten independent samples. ***p < 0.0001.
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the 6 GFP+ single cells were consistent with the whole 
exome data of the bulk DNA of the SMMC-7721 cell line, 
and at least 98.5%, of the SNPs were shared, whereas 
the SNPs of 3 GFP− single cells and the GFP− cell pool 
were consistent with those of peripheral blood cells of the 
healthy donor. These findings indicated that the 6 GFP+ 
single cells were derived from the SMMC-7721 cell line, 
and the 3 GFP- single cells and 1 GFP− pooled cells were 
derived from peripheral blood cells of the healthy donor. 
Moreover, the SNPs of the S2 subset of the 6 GFP+ 
single cells probably belonged to the shared SNPs (S3 
subset), but were not detected in the sequencing data of the 
bulk DNA of the SMMC-7721 cell line due to the different 
coverage of every SNP locus, as well as those of the S1 
subset of the 3 GFP− single cells and the GFP- cell pool. 
The S4 subset may represent specific mutations of each 
sample or false-positive calling of SNPs due to errors in 
whole genome amplification.
Identification of CTCs in patients with solid 
tumors and hematological malignancies
To determine whether CTCs from patients with 
solid tumors could be detected by oHSV1-hTERT-GFP, 
we analyzed 290 whole blood samples of patients with 
various cancer types. The positive threshold of > 3 CTCs 
per 4 ml blood was calculated based on ROC analysis 
(Figure 5A) of the CTC data from 178 healthy donors and 
290 solid tumor patients. CTCs from patients with both 
epithelial and non-epithelial solid tumors (Figure 5B) were 
detected, including 52 of 68 non-small cell lung cancer 
(NSCLC) adenocarcinomas (NSCLC-AC) (76.5%), 16 
of 19 NSCLC squamous cell carcinomas (NSCLC-SC) 
(84.2%), 9 of 14 small cell lung cancer (SCLC) (69.2%), 
51 of 68 colorectal cancers (CC) (75%), 25 of 29 gastric 
carcinomas (GC) (86.2%), 23 of 39 gliomas (59%), 33 
of 36 hepatocellular carcinomas (HCC) (91.6%), and 15 
Figure 3: Accuracy of the oHSV1-hTERTp-GFP detection method. Cancer cells (A) BGC823, (B) HuH7, and (C) SMMC-
7721 were added to 4 ml of whole blood from healthy donors and identified by the oHSV1-hTERTp-GFP detection method. The number 
of cancer cells spiked into whole blood versus the number of GFP-expressing cells detected is plotted. The sample size of each point was 
listed in the Supplmentary Tables 1, 2, and 3.  Each value represents the mean ± SD. (D) Typical mimic CTCs in the peripheral blood 
leukocytes of the blood sample spiked with 20 BGC823 cancer cells were treated with oHSV1-hTERTp-GFP. Typical spiked BGC823 cells 
were visualized using GFP expression by fluorescence microscope. Scale bar: 10 μm.
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Figure 4: Validation by single-cell sequencing. (A) Single CTCs sorted from peripheral blood samples from healthy donor spiked 
with 20 of SMMC-7721 cancer cells and observed by fluorescence microscopy. Each panel shows the fields from separate sorts. Original 
magnification, ×200. (B) The eGFP gene PCR products were analyzed by agarose gel electrophoresis. The order of samples: Marker, GFP-P1, 
GFP-P2, GFP-P3, GFP-P4, GFP-P5, GFP-P6, GFP-N1, GFP-N2, GFP-N3, GFP-NP, transduced SMMC-7721 cell line (iSMMC, positive 
control), non-transduced SMMC-7721 cell line (SMMC, negative control), peripheral blood cells of a healthy donor (PB, negative control), 
ddH2O, and Marker. Upper: GAPDH, lower: eGFP. (C) Circos map of the whole exomes of the unamplified bulk DNA, the pooled cells and 2 
single SMMC-7721 cells: A. Karyotype of the human reference genome (Hg19); B. GC content distribution of the whole exome (the heights 
of the orange rectangles ranged from 0–100%, and the whole exome was divided based on 1 Mb bins of the reference genome); C. Whole-
exome depth distribution of the unamplified bulk DNA of the SMMC-7721 cell line (the heights of the yellow rectangles ranged from 0–160X, 
the whole exome was divided based on 1 Mb bins of the reference genome); D. Whole-exome depth distribution of the pooled cells GFP-NP 
(the heights of the green rectangles ranged from 0–80X, and the whole exome was divided based on 1 Mb bins of the reference genome); E. 
Whole-exome depth distribution of cell GFP-P2 (the heights of the red rectangles ranged from 0–20X, and the whole exome was divided based 
on 1 Mb bins of the reference genome); and F. Whole-exome depth distribution of cell GFP-P3 (the heights of the blue rectangles ranged from 
0–20X, and the whole exome was divided based on 1 Mb bins of the reference genome). (D) Comparison of single nucleotide polymorphisms 
(SNPs) of the amplified DNA products of single-cell samples with unamplified bulk DNA of the SMMC-7721 cell line and peripheral blood 
cells of a healthy donor: SNPs of each sample were separated into 4 subsets (S1: the green section, consistent with the SMMC-7721 cell 
line only, S2: the pink section, consistent with peripheral blood cells of the healthy donor only, S3: the blue section, consistent with both the 
SMMC-7721 cell line and peripheral blood cells, and S4: the yellow section, not consistent with either the SMMC-7721 cell line or peripheral 
blood cells). Numbers of SNPs belonged to the subsets of each sample were marked on the pie charts. The upper 6 single cells belonged to the 
GFP-positive population, whereas the lower 3 single cells and the cell pool belonged to the GFP-negative population.
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of 17 pancreatic cancers (PC)(88.2%) (Supplementary 
Tables 5–11). The average numbers of detected CD45−/
GFP+ cells were 11.1, 9.1, 8.7, 15.0, 15.5, 6.5, 18.2, 
and 43.1 for NSCLC-AD, NSCLC-SC, SCLC, CC, GC, 
glioma, HCC, and PC patients, respectively (Figure 5C). 
The average numbers of CD45−/GFP+ cells were 0.63 
for healthy donor, while average CTC number for cancer 
patients was 10 to 68-fold higher. Although CTCs are 
significantly elevated on average, several patients with 
different cancer types did not have detection of CTC 
(≤ 3 cells)
The identity of the CTCs from non-small cell 
lung cancer patients isolated using our approach was 
validated by staining for the epithelial marker CK18. 
Representative confocal microscopy images are shown in 
Figure 5D. The cells that were identified as CTCs by their 
GFP expression were also marked by the CK18 antibody. 
Since the number of CTCs in HCC has been correlated 
with levels of the alpha-fetoprotein (AFP) HCC marker 
[34] (Schulze, Gasch et al. 2013), we performed 
similar comparison assessments. Thirteen of 36 HCC 
patients expressed AFP above the cut-off > 100 ng/ml. 
All these patients were also CTC-positive by oHSV1-
hTERT-GFP detection, and a positive correlation between 
CTC numbers and AFP levels was observed (r2 = 0.6592, 
p = 0.007) (Figure 5E). These findings suggested that the 
oHSV1-hTERT-GFP method can reliably detect CTCs in 
clinical practice. In agreement with other studies [35], 
CTCs were also detected in the peripheral blood of 
patients with primary gliomas (Figure 5B). In addition, 
abnormal cells that were most likely disseminated 
tumor cells (DTCs) were observed in cerebrospinal fluid 
(Supplementary Figure 2).
To determine whether this approach could also 
detect CTCs in patients with hematological malignancies, 
the number of GFP+ cells in blood samples of patients 
and healthy donors treated with oHSV1-hTERTp-GFP 
were analyzed. As shown in Supplementary Figure 3, 
the average GFP+ cells were 8.5 (4–15) per 105 total 
cells in control group (n = 100). In contrast, the GFP+ 
cells increased to a high level ranging from 19 to 687 per 
105 total cells for Non-Hodgkin’s lymphoma (n = 14), 
46–2767 per 105 total cells for natural killer/T cell Non-
Hodgkin’s lymphoma (NK/T) (n = 11), 121–807 per 105 
total cells for diffuse large B-cell lymphoma (n = 9), and 
343–609 per 105 total cells for Hodgkin’s lymphoma 
(n = 2) (Supplementary Table 12).
Positive CTC rates correlate well with cancer 
staging
To validate the sensitivity of the oHSV1-
hTERT-GFP detection method, positive CTC rates 
from 186 blood samples from patients with cancers at 
different stages were analyzed. As shown in Figure 6A 
and Tables 1 and 2, the CTC positive rates of patients 
with regional lymph node metastasis as determined by 
pathology, but without distant metastasis (N+M0) were 
81.3% for NSCLC-AD (37 of 48), 85.7% for NSCLC-
SC (6 of 7), 95.7% of HCC (22 of 23), 77.4% for colon 
cancer (24 of 31), 88.9% for gastric cancer (24 of 27), 
and 100% for pancreatic cancer (11 of 11), respectively. 
For patients with metastases to distant organs, the 
positive rates were 100% for all but pancreatic carcinoma 
(91.7%). Interestingly, 50%−60% positive CTC rates 
were observed for patients with biopsy-verified invasive 
malignancy at site of origin, but without regional nodal or 
distant metastasis (N0M0), suggesting that some N0M0 
patients might have nodal or distant micro-metastases that 
could not be detected by standard assessment. Similarly, 
the positive rate of CTCs in gliomas rose progressively 
with advancing stage of disease (Table 2). No statistical 
difference was observed between the percentages in stage 
M1 and N+M0 (Figure 6A).
Monitoring CTC counts following treatment of 
NSCLC patients and hematological malignancies
To evaluate the possibility of monitoring treatment 
responses in patients with solid organ malignancies 
using our approach, we further assessed CTC dynamics 
in NSCLC patients (n = 21) undergoing chemotherapy. 
As shown in Figure 6B, among 21 NSCLC cases in 
which CTC values were consecutively monitored, 81.0% 
(17 cases) showed decreased CTCs numbers in those with 
favorable treatment responses (Supplementary Table 13). 
A significant reduction in CTC  pre- and post-treatment 
was observed (p = 0.0056). Three representative NSCLC 
cases with reduced CTC numbers in response to treatment 
are shown in Figure 6C, 6D and 6E. The changes in 
CTCs numbers correlated well with clinical diagnosis 
and imaging. In 4 image traceable colon cancer patients, 
three being treated with chemotherapy and one undergoing 
surgery, CTC numbers decreased 4 weeks after treatments 
(Figure 6F and 6G). 
In addition, CTC numbers in 6 follow-up 
lymphoma patients after two cycles of chemotherapy 
all showed decreased average CTC counts, and 4 of 
which were significant. Moreover, the reduction in 
CTCs correlated well with the clinical evaluation of 
apparently curative effect (Supplementary Figure 4). 
The results from a representative patient (case 6) with 
non-Hodgkin’s lymphoma are shown in Supplementary 
Figure 4. The patient recrudesced 90 days after 
chemotherapy, and the average number of CTCs per 105 
rose from 350 to 1,354. These results suggest that the 
number of CTCs could be useful for monitoring clinical 
treatment response and disease recurrence in patients 
with solid organ epithelial cancers or hematological 
malignancies.
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Comparison of CTC detection using oHSV1-
hTERT-GFP and CellSearch
To compare our CTC detection method with that 
of CellSearch (Janssen Diagnostics, Raritan, NJ), blood 
samples from 40 lung adenocarcinoma patients were 
simultaneously analyzed using the two methods. The 
numbers of CTCs detected by oHSV1-hTERT-GFP ranged 
from 0 to 33 (Figure 7A, Supplementary Tables 14 and 15), 
while the numbers of CTCs detected by CellSearch ranged 
from 0 to 27. Higher CTC numbers were detected by 
oHSV1-hTERT-GFP vs. CellSearch, and CTC-positive 
rates were significant higher in the former (p < 0.0001). 
Similar results (positive or negative, respectively) were 
obtained by both methods in 57.5% of samples (23 of 40), 
while 35% (14 of 40) were only CTC-positive by oHSV1-
hTERT-GFP. Of the 40 lung cancer patients, 20 had 
blood samples taken during chemotherapy, while the 
Table 2: Detection of CTCs in patients with various cancer types using oHSV1-hTERT-GFP 
Type TNM or Grade Number of patients with > 3 CTCs
Total number of 
patients Sensitivity*
Hepatocarcinoma
N0 M0 11 13 0.846
N+ M0 22 23 0.957
M1 12 12 1
Colon carcinoma N0 M0 4 8 0.5
N + M0 47 60 0.783
M1 22 22 1
Gastric carcinoma N0 M0 1 2 0.5
N + M0 24 27 0.889
M1 8 8 1
Pancreatic carcinoma N0 M0 3 6 0.5
N + M0 11 11 1
M1 11 12 0.917
Glioma
II 11 23 0.478
III 9 13 0.692
IV 12 15 0.8
Note: * Sensitivity = Number of patients with >3 CTCs / Total number of patients.
Table 1: Detection of CTCs in lung cancer patients using oHSV1-hTERT-GFP 
Type TNM or stage Number of patients with > 3 CTCs 
Total number of 
patients Sensitivity*
Adenocarcinoma
T1N0M0 3 4 0.75
N0M0 12 20 0.6
N + M0 37 48 0.813
M1 15 15 1
Squamous cell carcinoma N0 M0 2 4 0.5
N + M0 6 7 0.857
M1 5 5 1
Small cell lung cancer LS 1 4 0.25
ES 8 10 0.8
Note: * Sensitivity = Number of patients with > 3 CTCs/Total number of patients. ES, Extensive stage; LS, Limited stage.
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Figure 5: Identification of CTCs in patients with solid tumors. (A) ROC analysis for threshold detection of CTCs. The threshold 
was determine by compared patients and controls by ROC analysis, identifying the threshold to 3 cells, and consequently measurements of 
> 3 CD45–/GFP+ cells was considered positive. A significant difference between patients and controls was observed (p < 0.001; area under 
the curve (AUC) = 0.937; 95% confidence interval = 0.914–0.960). (B) Positive rate for epithelial and non-epithelial cancer, including SCLC, 
glioma, and lymphoma. (C) Enumeration of CTCs in peripheral blood of solid tumor patients. CTC counts in 4-ml blood samples from 290 
patients with solid cancers, 68 with NSCLC adenocarcinoma, 19 with NSCLC squamous carcinoma, 14 with small cell lung cancer, 68 with 
colorectal cancer, 29 with gastric cancer, 39 with glioma, 36 with hepatocellular carcinoma, and 17 with pancreatic cancer. Approximately 
1 × 107 cells were counted in 4ml of blood from patients with solid tumors. (D) Typical CTCs in the peripheral blood leukocytes of the blood 
sample were visualized using GFP expression. The blood samples were incubated with oHSV1-hTERT-GFP, then stained with Alexa Fluor® 
647-labeled anti-CK18 antibody. Overlap of green (GFP) and red (CK18) fluorescence was displayed as yellow fluorescence. Approximately 
80% of GFP+ cells were CK18+. Scale bar, 10 μm. (E) Correlation of CTCs and AFP in HCC patients (n = 13, the best-fit line and 95% 
confidence bands are indicated). Each dot represents an individual blood sample; 95% confidence interval, 9.500 to 26.84. 
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other 20 were obtained prior to chemotherapy. The CTC-
positive rates of samples obtained during chemotherapy 
were 25% (5 to 20) for CellSearch and 70% (14 to 20) 
for oHSV1-hTERT-GFP, while CTC-positive rates for 
the samples obtained prior to chemotherapy were 55% 
(11 to 20) for CellSearch and 75% (15 to 20) for oHSV1-
hTERT-GFP (Figure 7B and 7C). This indicates that 
cytotoxic systemic therapy had less impact on oHSV1-
hTERT-GFP detection than on CellSearch in comparably 
staged patients. Interestingly, correlation of CTC-positive 
rates with TNM stages showed that oHSV1-hTERT-GFP 
was much more sensitive than CellSearch in lung cancers 
with regional lymph node metastasis or distant metastasis 
(Supplementary Table 16). The CTC-positive rates of 
N0M0 patients determined by pathology were 36.4% for 
CellSearch (4 of 11) and 54.5% for oHSV1-hTERT-GFP 
(6 of 11). The positive rates of N+M0 patients were 41.4% 
for CellSearch (12 of 29) and 75.9% for oHSV1-hTERT-
GFP (22 of 29). Strikingly, CTCs for patients with distant 
metastasis were 100% positive (9 of 9) by oHSV1-hTERT-
GFP vs 33.3% positive (3 of 9) by CellSearch. These 
observations strongly indicate that oHSV1-hTERT-GFP is 
a more sensitive assessment tool than CellSearch in lung 
cancer patients across the spectrum of disease. 
DISCUSSION
We established a reliable cell surface marker-
independent approach to enumerate CTCs from as little as 
4 ml of peripheral blood samples via tumor-specific HSV-
transduced GFP. Our results show that this assessment 
methodology can more accurately determine CTC numbers to 
quantify circulating tumor cells, including EpCAM-negative 
CTCs, in patients with solid tumors, as well as identify 
CTCs in patients with hematological malignancies. More 
importantly, viable CTCs detected by this approach may serve 
as a reliable biomarker for monitoring tumor progression and 
therapeutic responses, making it a very useful clinical tool. 
CTC detection methods with high sensitivity and 
specificity are in great demand for clinical application. 
Receiver operating characteristics (ROC) curve analysis 
of samples from 178 healthy donors and 290 patients 
with various solid tumors detected by oHSV1-hTERT-
GFP generated a threshold of > 3 CTCs per 4 ml blood 
that differentiated cancer patients vs. healthy individuals. 
The threshold of hematological malignancies was 17 CTCs 
per 105 cells based on ROC analysis. Our data confirmed 
the sensitivity of this method as well as the relatively high 
specificity for detection of CTCs from various cancer types.
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Figure 6: Correlations between CTC-positive rates and cancer stage or treatment response. (A) Positive rates of CTC 
numbers for patients with cancer at different TNM stages detected by oHSV1-hTERT-GFP. AC: adenocarcinoma (NSCLC); SC: squamous 
carcinoma (NSCLC); HCC: hepatocellular carcinoma; CC: colorectal cancer; GC: gastric carcinoma; PC: pancreatic cancer. (B) Detection 
of patients with non-small cell lung cancer (adenocarcinoma) and their CTC numbers during or after chemotherapy. **p = 0.0056. (C) 
Changes in CTC numbers in response to treatment in a patient with stage III NSCLC using oHSV-hTERT-GFP. The numbers of CTCs were 
30, 15, 9, and 15 at different time points, respectively. Upper: spine CT cross-sectional images, Middle: chest CT cross-sectional images, 
Tu: tumor. (D) CTC changes in response to treatment in a patient with stage III NSCLC using oHSV-hTERT-GFP. The numbers of CTCs 
were 9, 42, 11, and 14 at different time points, respectively. Upper: brain CT cross-sectional images, Middle: chest CT cross-sectional 
images, Tu: tumor. (E) CTC changes in response to treatment in a patient with stage III NSCLC using oHSV-hTERT-GFP or CellSearch. 
The numbers of CTCs were 6, 8, 10, and 36 at different time points for oHSV1-hTERT-GFP, respectively, and 2, 0, 0, and 0 at different time 
points for CellSearch, respectively. Upper: chest CT cross-sectional images, Tu: tumor. (F) Changes in CTC numbers after chemotherapy 
of three colorectal cancer cases. (G) Changes in CTC numbers after surgery of colorectal cancer cases. 
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Although efforts have been made to improve the 
accuracy and sensitivity of cancer diagnoses, earlier 
detection of metastasis received less attention. Our 
approach has shown the potential for early detection of 
micro residual disease, especially in patients with N0M0 
stage. Interestingly, our data showed 50% of N0M0 
patients also had detectable CTCs. Since current staging 
criteria for cancers primarily relies on information from 
pathology and surgical reports, micro-metastases are 
often overlooked with current standard histopathological 
techniques. It has been shown that 30–40% of patients with 
stage I NSCLC suffer post-operative local recurrence and 
distant metastasis despite pathologically-confirmed N0M0 
[36, 37, 38], suggesting that the pathological stage defined 
Figure 7: Comparison of CTC detection using oHSV1-hTERT-GFP and CellSearch methods. (A) Detection of CTCs 
in peripheral blood of non–small cell lung cancer patients by CellSearch and oHSV1-hTERT-GFP. n = 40. (B–C) The CTC positive of 
NSCLC patients detected by CellSearch or oHSV1-hTERTp-GFP during chemotherapy treatment (B) or before chemotherapy treatment 
(C). ns, no significant difference, **p < 0.0005, ***p < 0.0001.
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by routine histopathology using lymph node cancers may 
underestimate rates of node-positive disease. Patients with 
early stage disease such as T0N0 should be followed in 
subsequent studies to clarify the relationship between the 
disease-free interval or survival with the number of CTCs 
in these subset of patients. CTCs from all patients with 
pathologically-determined distant metastases were almost 
uniformly positive when tested by our method except for 
a single pancreatic cancer patient in which CTCs may 
have been telomerase-negative or enter the blood stream 
intermittently. CTCs for patients with regional lymph 
node metastasis also showed > 70% positivity rates in all 
cancer types tested, indicating CTCs are common and thus 
detectable at this stage of cancer progression. Our data 
showed that oHSV1-hTERT-GFP effectively monitored 
patients with micro-metastasis, which would clearly assist 
clinicians in making more accurate judgments. 
Our patient data showed that the number of 
viable CTCs accurately reflects the clinical response. 
Although the patient number in this study is limited, 6 
hematological malignancy patients and 3 NSCLC patients 
exhibited a relevant decrease of CTC counts in response 
to chemotherapy, whereas a recrudescent hematological 
malignancy patient had a dramatically increased CTC 
count, validating the correlation of CTC numbers with 
disease progression. A sharp increase in CTC numbers 
thus indicates therapeutic failure or exacerbations during 
chemotherapy, suggesting that this approach may be even 
more valuable with occult disease and treatment response.
To date, a variety of methods have been established 
to isolate and enumerate CTCs, [13, 23, 39, 40, 41], but 
some shortcomings remain to be overcome. Our approach 
can be easily utilized in the absence of any tumor cell 
surface markers. CTCs can be identified and serially 
monitored whether patients have or have not received 
treatment, implying that oHSV1-hTERT-GFP is a reliable 
approach for CTC detection. In addition, combined with 
flow cytometry, our strategy allows a high-throughput 
detection methodology of a broad range of CTCs and 
isolation of single-cell CTCs for genomic analysis that will 
extend our current understanding of CTCs. Furthermore, 
CTCs under EMT or other biological changes due to novel 
mutations in the cancer cell genome may still be detected 
by our approach, which facilitates dynamic monitoring of 
CTCs for treatment response and tumor progression. 
In conclusion, we have developed a robust HSV-based 
approach that is easily applicable in the clinic for accurate 
identification and sorting of viable CTCs from a broad 
spectrum of epithelial and non-epithelial malignancies. The 
approach has the potential to monitor tumor progression, 
predict prognosis, and evaluate therapeutic efficacy of 
individualized treatments. This is the first report showing 
that tumor-selective replicating HSV with GFP expression 
can be used for fast and robust detection of viable CTCs. 
Further, this method allows isolation of single CTCs for 
subsequent genetic and molecular analyses.
MATERIALS AND METHODS
Patient recruitment and sample collection
Eligible patients were diagnosed with hepatocellular 
carcinoma (HCC), gastric carcinoma, colon cancer, non–
small cell lung cancer (NSCLC), glioma or lymphoma. 
The study was approved by the Cancer Institute & 
Hospital ethics committee. Clinical information of 
the included patients is provided in Supplementary 
Tables 5–12. All patients had metastatic solid cancers or 
hematological malignancies and were undergoing active 
treatment. The healthy donor age range was 20–50 years 
old. All patients provided written informed consent for 
collection of tissue and blood and analyses of clinical 
and genetic data for research purposes. Four ml blood 
was prospectively collected from eligible patients in 
heparinized tubes and transported on ice to the lab within 
1 hour.
Identification of samples with solid tumors
Peripheral blood samples (4 ml) were prepared in 
heparinized tubes and incubated with lysis buffer (NH4Cl, 
0.15 M; EDTA, 0.1 mM; KHCO3, 10 mM; pH = 7.2) at 
RT for 5 minutes. After centrifugation, supernatant was 
discarded and cell pellets were washed 2× with PBS. 
Following centrifugation, cells were resuspended and 
transduced with oHSV1-hTERT-GFP at an MOI = 1 at 
37°C in a humidified atmosphere of 5% CO2 for another 
24 hours. Thereafter, the cells were gathered, 200 μl 
PE- Cy5 mouse anti-human CD45 (HI30, BD, USA) was 
added and incubated in the dark at room temperature for 
30 minutes. After one wash with PBS, the cells were 
resuspended in 1 ml PBS. Detection of CD45−/GFP+ 
cells for solid tumor blood samples were executed by 
flow cytometry (Merck Millipore, Germany or BD, 
USA). The CD45−/GFP+ cells were recorded as positive 
results.
Identification of CTCs with hematological 
malignancies
Peripheral blood samples (4 ml) were prepared in 
heparinized tubes and incubated with lysis buffer (NH4Cl, 
0.15 M; EDTA, 0.1 mM; KHCO3, 10 mM; pH = 7.2) at 
RT for 5 minutes. After centrifugation, supernatant was 
discarded and cell pellets were washed x2 with PBS. 
Following centrifugation, cells were resuspended and 
transduced with oHSV1-hTERTp-GFP at an MOI = 1 at 
37°C in a humidified atmosphere of 5% CO2 for another 
24 hours. Thereafter, cells were gathered and detection of 
GFP+ cells for hematological malignancies was performed 
by flow cytometry (Merck Millipore, Germany or BD, 
USA). GFP+ cells of more than 17 were recorded as 
positive.
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Immunofluorescence analysis 
Peripheral blood samples were pretreated as 
mentioned above. The cells were gathered after incubation 
with oHSV1-hTERT-GFP for 24 hours. Alexa Fluor® 647 
anti-Cytokeratin 18 antibody (DA-7, Biolegend, USA) 
was added and incubated in the dark at room temperature 
for 30 minutes. After one wash with PBS, the cells were 
resuspended in 1 ml PBS and CTCs were recorded by 
confocal microscopy (LEICA DMI RE2, Germany).
Virus
The oHSV1-hTERT-GFP virus with the endogenous 
ICP4 promoter replaced with the hTERT promoter has 
been described in our previous work (42).The purified 
viruses were dissolved in SFM, titrated, divided into 
aliquots, and stored at −80ºC until use. 
Cell culture
The tumor cell lines PC-3, HepG2 and MCF-
7 were purchased from ATCC and maintained in our 
laboratory. The tumor cell lines HuH7, BEL-7402, 
SMMC-7721, PLC/PRF5, A549, HOS, and Wi-38 
were purchased from the Cell Resource Center (IBMS, 
CAMS/PUMC). The BGC823 cell line was a gift from 
BGI-Shenzhen (Shenzhen, China). The human liver 
hepatocellular carcinoma cell lines HuH7, HepG2, 
BEL- 7402, SMMC- 7721 and PLC/PRF5, the human 
lung adenocarcinoma cancer cell line A549, the human 
gastric cancer cell line BGC823, the human osteosarcoma 
cell line HOS, the human prostate cancer cell line PC-3, 
and the human mammary gland adenocarcinoma cell line 
MCF-7 were cultured in DMEM/F12 medium (Invitrogen, 
USA) supplemented with 10% fetal bovine serum (FBS). 
The human glioma cell line U251 was cultured in MEM 
medium (Invitrogen, USA) supplemented with 10% FBS. 
The normal human fetal lung fibroblast cell line Wi-38 was 
cultured in MEM medium supplemented with 1% NEAA 
and 10% FBS. All cell lines were incubated at 37°C in a 
humidified atmosphere of 5% CO2 (Sanyo, Japan).
Quantitative real-time RT-PCR
Total RNA was extracted from cultured cells 
using the TRIZOL reagent (Invitrogen, USA) according 
to manufacturer’s instructions. The cDNA library 
was then reverse transcribed using the ReverTra Ace 
qPCR RT Master Mix kit (Toyobo, Japan) according 
to manufacturer’s instructions. The following specific 
primers were used: hTERT, forward primer, 5ʹ-CCGATT 
GTGAACATGGACTACG-3ʹ and reverse primer, 5ʹ-CACG 
CTGAACAGTGCCTTC-3ʹ; and GAPDH, forward primer, 
5ʹ-TGTGGGCATCAATGGATTTGG-3ʹ and reverse primer, 
5ʹ-ACACCATGTATTCCGGGTCAAT-3ʹ. Quantitative 
RT-PCR (qRT-PCR) was performed using the SYBR 
Green I Mix kit (Toyobo, Japan) with a 7300 Real-Time 
PCR System (ABI, USA), as described. Each sample 
was run in triplicate, and the expression of each gene 
was presented as the ratio of the expression of the TERT 
mRNA and GAPDH mRNAs.
GFP fluorescence intensity analysis
The cells were seeded in 6-well plates. After 
treatment with virus at an MOI of 0.1 for 48 h, the cells 
were harvested and analyzed by flow cytometry for GFP 
fluorescence intensity.
Single-cell lysis and whole-genome amplification 
(WGA) of single cells
After isolation of single cells by flow cytometry, each 
cell was immediately transferred into a precooled PCR 
tube containing cell lysis solution on ice. A physiological 
saline blank was included as a negative control. WGA was 
performed using the REPLI-g Single Cell Kit according to 
the manufacturer’s manual (Qiagen GmbH). All amplified 
DNA products were then stored at –20°C.
Concentration measurements and whole-exome 
sequencing
The QubitTM Quantitation Platform (Life 
Technologies) was used to measure concentrations of 
the WGA products. Thereafter, successfully amplified 
products with DNA yields reaching more than 1.5 µg 
were selected for further whole-exome sequencing using 
the SeqCap EZ Human Exome Library v3.0 (Roche 
NimbleGen) and HiSeq2000 platform (Illumina).
Single-cell sequencing data analysis
Following whole-exome sequencing, reads were 
aligned to the NCBI human reference genome (hg19) 
using BWA (v0.5.9), duplicates were removed by Picard 
(v1.54), and calling of SNPs was performed using the 
Genome Analysis Tool Kit pipeline. SNPs detected in the 
amplification products of the single-cell samples were 
filtered by the quality cutoff value of 50 for comparison 
with SNPs of the SMMC-7721 cell line and the peripheral 
blood of the healthy donor to identify the source of the cells. 
To avoid random deviations of calling SNPs, we selected 
regions where the SMMC-7721 cell line and peripheral 
blood of the healthy donor both covered with depth greater 
than 30×.
Statistics
All quantitative data are reported as the mean ± 
SED. Statistical analysis was performed for multiple 
comparisons using analysis of variance, Student’s t-tests, 
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and Chi-square test. The accuracy of the detection method 
and the association between bio-markers and number of 
CTCs was analyzed using linear regression as appropriate. 
The SPSS 15 software package (SPSS, Inc.) was used 
for ROC analysis. A P value < 0.05 was considered 
statistically significant.
Study approval
All protocols involving patients were approved by 
the Cancer Institute & Hospital ethics committee.
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